 NEW YORK, May 20, 2021 PRNewswire -- Seelos Therapeutics, Inc. Nasdaq: SEEL, a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system CNS disorders and rare diseases, announced today the pricing of an underwritten public offering of 19,354,840 shares of its common stock, at a price to the public of 3.10 per share. In addition, the Company granted the underwriters a 30-day option to purchase up to 2,903,226 additional shares of its common stock. 